Publications by authors named "Kenneth Truitt"

Claim this Profile
E
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.
Jason A Tye-Din, A James M Daveson, Gautam Goel, Kaela E Goldstein, Holly L Hand, Kenneth E Truitt

Lancet Gastroenterol Hepatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease.
Melinda Y Hardy, Gautam Goel, Amy K Russell, Swee Lin G Chen Yi Mei, Gregor J E Brown, Kenneth E Truitt

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease.
Jason A Tye-Din, A James M Daveson, Kaela E Goldstein, Holly L Hand, Kristin M Neff, Kenneth E Truitt

BMC Med· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease.
A James M Daveson, Jason A Tye-Din, Gautam Goel, Kaela E Goldstein, Holly L Hand, Kenneth E Truitt

Aliment Pharmacol Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease.
Jason A Tye-Din, A James M Daveson, Hooi C Ee, Gautam Goel, James MacDougall, Kenneth E Truitt

Aliment Pharmacol Ther· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: a non-dietary treatment for coeliac disease-two steps forward, one step back? Authors' reply.
Kenneth E Truitt, Robert P Anderson

Aliment Pharmacol Ther· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease.
Kenneth E Truitt, A James M Daveson, Hooi C Ee, Gautam Goel, James MacDougall

Aliment Pharmacol Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Ophelia Q P Yin, Elliott M Antman, Eugene Braunwald, Michele F Mercuri, Raymond Miller, Kenneth Truitt

Circulation· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Dolly A Parasrampuria, Jeanne Mendell, Minggao Shi, Nobuko Matsushima, Hamim Zahir, Kenneth Truitt

Br J Clin Pharmacol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Dolly A Parasrampuria, Kenneth E Truitt

Clin Pharmacokinet· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin.
Ophelia Q P Yin, Domenico Merante, Kenneth Truitt, Raymond Miller

J Clin Pharmacol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain.
Matthew M Hutmacher, Bill Frame, Raymond Miller, Kenneth Truitt, Domenico Merante

J Clin Pharmacol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of colesevelam HCl in the treatment of elderly patients.
James R Gavin, Michael R Jones, Daniel M Ford, Kenneth E Truitt

Drugs Aging· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator.
James B Moberly, Shashank Rohatagi, Hamim Zahir, Ching Hsu, Robert J Noveck, Kenneth E Truitt

J Clin Pharmacol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients.
James B Moberly, Daniel M Ford, Hamim Zahir, Shuquan Chen, Takashi Mochizuki, Kenneth E Truitt

J Neuroimmunol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetic macular edema: correlations with available diabetes therapies--evidence across a qualitative review of published literature from MEDLINE and EMBASE.
Domenico Merante, Francesca Menchini, Kenneth E Truitt, Francesco M Bandello

Drug Saf· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.
Kenneth E Truitt, Ronald B Goldberg, Julio Rosenstock, Hubert S Chou, Domenico Merante

Curr Med Res Opin· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator.
Shashank Rohatagi, Hamim Zahir, James B Moberly, Kenneth E Truitt, Shin-ichi Inaba

J Clin Pharmacol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs.
Shashank Rohatagi, Timothy J Carrothers, Jinyan Jin, William J Jusko, Tatiana Khariton, Kenneth Truitt

J Clin Pharmacol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.
Harold E Bays, Ronald B Goldberg, Kenneth E Truitt, Michael R Jones

Arch Intern Med· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.
Vivian A Fonseca, Julio Rosenstock, Antonia C Wang, Kenneth E Truitt, Michael R Jones

Diabetes Care· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain.
Shashank Rohatagi, Helen Kastrissios, Kunihiro Sasahara, Kenneth Truitt, James B Moberly

Br J Clin Pharmacol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
Ronald B Goldberg, Vivian A Fonseca, Kenneth E Truitt, Michael R Jones

Arch Intern Med· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain.
James B Moberly, Jianbo Xu, Paul J Desjardins, Stephen E Daniels, Donald P Bandy, Kenneth E Truitt

Clin Ther· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa.
James B Moberly, Stuart I Harris, Dennis S Riff, James Craig Dale, Tara Breese, Kenneth E Truitt

Dig Dis Sci· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis